STI Stock Trade Intelligence
SNT

SYNTARA LIMITED

Health Care · ASX:SNT
$0.0140
0.00%
Market cap
$28M
Turnover
$32,694
Last price
$0.0140
Day change
0.00%
Announcements
20
Range, past year
Open 0.031 · Low 0.013 · Now 0.014 · High 0.083
Open SNT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

SNT momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
22/100
Wyckoff phase
Downtrend19d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-26.3%
1 Month
-26.3%
1 Year
-53.3%
RSI
29
Avg daily range
11.6%

SYNTARA LIMITED scores 22 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.

On the Wyckoff cycle it sits in Downtrend, where it has been for 19 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.80 — highly linear uptrend
Points to watch
  • RSI oversold (29)
  • 60d drawdown -48.1%
  • High volatility (ATR 11.6%)
  • Thin liquidity
  • Risk rating: Very High
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

SNT announcements

Recent price-sensitive releases.
  • 2026-11-10 Syntara Pauses SNT-9465 Phase 1b Recruitment Progress Report
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-07 Further significant results from SNT-4728 iRBD Phase 2 trial Progress Report
  • 2026-10-01 Syntara expands SNT-9465 skin scarring study Progress Report
  • 2026-08-27 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-27 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-06 Encouraging SNT-4728 Phase 2 iRBD results
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.